Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Not listed Phase 1Phase 2 Interventional

Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease

NCT01099332
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Gastro-retentive zinc cysteine tablet, Tablet identical physically to active comparator containing some lactose
Other
Lead sponsor
Adeona Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Clearwater, Florida • Holiday, Florida • Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2011 · Synced Oct 21, 2026, 2:18 PM EDT
Terminated Phase 3 Interventional

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

NCT05065411
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
30
States / cities
Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A First in Human Study of RT001 in Patients With Friedreich's Ataxia

NCT02445794
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Low dose cohort, High dose cohort
Drug
Lead sponsor
Biojiva LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Long Beach, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

NCT00681356
View directory record Official record
Conditions
Total Knee Arthroplasty (Replacement)
Interventions
4975, 15 and 5 mg, Placebo Comparator, 4975 - 5 mg
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Ohio RETAIN Impact Evaluation

NCT05219045
View directory record Official record
Conditions
Disability
Interventions
Ohio RETAIN
Other
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
4,525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT04740905
View directory record Official record
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

NCT00511953
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended Release tablets, Gabapentin
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Burbank, California • DeLand, Florida • Port Orange, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Feasibility & Acceptability of App-based Cognitive Behavioral Therapy for Postpartum Depression Prevention

NCT06365645
View directory record Official record
Conditions
Postpartum Depression, Postpartum Anxiety, Stress
Interventions
M.Bapp, App-based parenting education
Behavioral
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC

NCT03927703
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
6 Months and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
27
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 21, 2026, 2:18 PM EDT
Terminated Not applicable Interventional Results available

Educational-Medical-Behavioral Treatment of Fecal Incontinence

NCT01717456
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Education, Fiber supplements, Laxatives or anti-diarrheals, Pelvic floor muscle exercises, Tips on how to prevent fecal incontinence, Daily diary, Protective pads or garments
Other · Dietary Supplement · Drug + 1 more
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 21, 2026, 2:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health

NCT05353322
View directory record Official record
Conditions
Sedentary Behavior, Cardiometabolic Risk Factors, Blood Pressure, Glucose
Interventions
Sedentary Break (Walking) Condition, Sitting (Control) Condition, Controlled Diet
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrative Psychosocial Group Treatment

NCT03648177
View directory record Official record
Conditions
Chronic Pain, Opioid Misuse
Interventions
IPGT, Treatment as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Not applicable Interventional Results available

Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis

NCT02107482
View directory record Official record
Conditions
Psoriasis
Interventions
Levia Narrow Band UVB, Levia sham/visible-light source
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

NCT00368108
View directory record Official record
Conditions
Parkinson's Disease
Interventions
2 mg perampanel, 4 mg perampanel, placebo comparator
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
99
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 21, 2026, 2:18 PM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

RHA® 3 Versus Restylane-L® for Lip Augmentation

NCT04540913
View directory record Official record
Conditions
Lip Augmentation, Lip
Interventions
RHA 3, Restylane-L
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

NCT01172808
View directory record Official record
Conditions
Asthma
Interventions
Placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Huntington Beach, California • Mission Viejo, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF

NCT02808585
View directory record Official record
Conditions
Heart Failure
Interventions
PB1046 Injection, Placebo Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anniston, Alabama • Peoria, Arizona • Daytona Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Varenicline In-Patient Study

NCT01413516
View directory record Official record
Conditions
Smoking Cessation
Interventions
Smoking cessation counseling, Placebo, Varenicline
Behavioral · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Phase 1 Interventional

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

NCT06714955
View directory record Official record
Conditions
Non-diabetic Overweight or Obese
Interventions
Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week., Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week., Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.
Drug
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 21, 2026, 2:18 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Scalable Interventions to Increase PrEP Adherence: Value Affirmation and Future Selves

NCT03278990
View directory record Official record
Conditions
HIV Prevention
Interventions
Value Affirmation and Future Selves Combination, Control writing exercise
Behavioral
Lead sponsor
Stuart Fisk
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 21, 2026, 2:18 PM EDT
Recruiting Phase 2Phase 3 Interventional

Randomized Controlled Trial of Treatment to Optimize Heart Rate Variability for Persistent Post-Concussion Symptoms

NCT07071350
View directory record Official record
Conditions
Autonomic Nervous System Disease, Concussive Injury, Mild Traumatic Brain Injury, Post Traumatic Stress Disorder, Persistent Post Concussion Syndrome
Interventions
HRV Coherence Ratio, NSI, Pittsburgh Sleep Quality Index (PSQI), Quantitative Sleep Measures, Patient Global Impression of Change (PGIC), Cognitive Performance/NIH Toolbox Cognitive Battery, Pain Interference/TBI-QoL Pain Interference Short-Form, Patient Health Questionnaire-9 (PHQ-9), PTSD Checklist for DSM-5 (PCL-5), HRV Biofeedback (HRV-B), Psychoeducational (Edu) Comparator Intervention
Other · Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 2:18 PM EDT
Recruiting Not applicable Interventional

Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression

NCT07127913
View directory record Official record
Conditions
Bipolar II Disorder, Bipolar II Disorder, Most Recent Episode Major Depressive
Interventions
Device: Stimulation-ON, Device: Stimulation-OFF, Device: Stimulation -ON Active Control
Device
Lead sponsor
Andrew Krystal
Other
Eligibility
22 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Phase 4 Interventional Results available

Preventing Staphylococcal (Staph) Infection

NCT00108160
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
Mupirocin Ointment [Treatment], Polyethylene Glycol Ointment [Placebo]
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

NCT00550446
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Adalimumab, CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
22
States / cities
Mesa, Arizona • Little Rock, Arkansas • Northridge, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 21, 2026, 2:18 PM EDT